Risk of Ocular Adverse Events with Taxane Based Chemotherapy

INTRODUCTION

Chemotherapy remains the mainstay therapy for most cancers including breast cancer, lung cancer, genitourinary cancers and head and neck cancers¹. Although much is known about adverse events related to taxanes such as docetaxel (DTX) and paclitaxel (PTX), information on the frequency of ocular adverse events including their incidence is scant. A number of ocular adverse events secondary to PTX or DTX have been published which have mainly focused on 1) epiphora^2-4, 2) cystoid macular edema (CME^5,6), and 3) optic neuropathy⁷. Epiphora is a significantly debilitating condition that may be irreversible and greatly affects quality of life, in particular, outdoor activities⁸ and research has shown that if treatable, correction of epiphora can vastly improve overall health and quality of life⁹. CME and optic neuropathy are also serious adverse events, and their prompt diagnosis and treatment can affect patient outcomes. Most of the data on these three adverse events with PTX and DTX have been mainly reported as case reports which cannot quantify a true incidence or provide an effect size as to the magnitude of these events.

In 2020 more than 2 million women were diagnosed with breast cancer around the world¹⁰. Approximately 60% of women with breast cancer are diagnosed with invasive breast cancer. which usually require chemotherapy that includes PTX or DTX¹¹. Therefore, ophthalmologists and oncologists need to be familiar with the frequency and type of ocular adverse advents secondary to taxane chemotherapy. Recognizing these ocular adverse events early will potentially prevent complications and improve patient outcomes. Therefore, we sought to quantify the risk of these adverse events by undertaking a large pharmacoepidemiologic study.

METHODS

RESULTS

For the epiphora analysis there were 1,824 taxane users (PTX or DTX) and 16,395 tamoxifen users. The incidence of epiphora among taxane users was 55.6/10,000 person years vs. 7.9/10,000 years for tamoxifen users. The crude HR for this association was 7.32 (95% CI: 4.25-16.61) and adjusted HR of 5.15 (95% CI: 2.79-9.54). For the CME analysis there were 1,909 taxane user and 16,524 tamoxifen users. The incidence of CME among taxane users was 34.8/10,000 vs. 16.8/10,000 users in the tamoxifen users. The crude HR for CME comparing taxane users to tamoxifen users was 1.37 (95%CI :0.72-2.60) and the adjusted HR was 1.33 (95% CI: 0.70-2.53). For optic neuropathy there were 1,913 taxane users and 16,566 tamoxifen users. The incidence of optic neuropathy for taxane users was 10.6/10,000 1.2/10,000 for tamoxifen users. The crude HR was 4.43 (95% CI: 1.10-17.82) and the adjusted HR was 4.44 (95% CI: 1.04-18.87). When we restricted our analysis to only cases of toxic optic neuropathy the aged-matched HR remained elevated (HR=7.24, 95% CI: 1.13-46.36).

DISCUSSION

The results of our study suggests that taxane based chemotherapy agents can increase in the risk of epiphora and optic neuropathy. There was also an elevated risk with CME, but results were not precise and confidence intervals were wide (HR=1.33, 95% CI :0.70-2.53). Our study results are consistent with published case-reports that have suggested an increase in the risk of these three important ocular adverse events^2,5,8.

There is a paucity of evidence surrounding the potential pathophysiological mechanism of taxane induced optic neuropathy. It has been hypothesized that the systemically administered taxanes can cause neurotoxic or ischemic damage to the retinal ganglion cells⁷. Other research has shown that taxanes can induce maladaptive electrophysiological changes within the retina and optic nerve which were attributed to vasospasm or vascular dysregulation¹⁵. This hypothesis is supported by findings from case studies such that the patient presentation of taxane induced optic neuropathy resembles that of interferon alpha therapy, which is also believed to be caused by ischemia and vascular dysregulation⁷. Furthermore, since taxanes are known to be neurotoxic and can cause peripheral neuropathy, it is possible that the optic nerve is damaged via a similar mechanism¹⁶.

The proposed mechanism for taxane induced epiphora is canalicular stenosis. The drug is secreted in the tear film, and chronic inflammation of the canaliculi as these tears are drained through the nasolacrimal system results in scarring and narrowing of the passageway.^{2, 17}. However, epiphora has also been shown to occur in the absence of canalicular stenosis and is believed to be secondary to dry eye disease caused by taxane based chemotherapy². The use of artificial tears may not only serve to dilute and clear the drug from the ocular surface through the nasolacrimal system, but may treat any related dry eye disease. Early recognition and discontinuation of the drug if possible, may prevent surgical intervention¹⁷. Alternatively, silicone intubation may be an option to manage canalicular stenosis in the early stages. However, delayed diagnosis and management may lead to obstruction along the nasolacrimal system necessitating more complex surgery¹⁷.

It has been postulated that CME can result of a disruption of the retinal-blood barrier and fluid accumulation in intracellular spaces¹⁸. Some have also proposed that taxanes can cause retinal cell toxicity by due to taxanes inherent mechanism of inhibiting microtubular reorganization¹⁸.

There are more than 2 million women suffering from breast cancer worldwide¹⁰ and more than 60%¹¹ of these women are likely undergoing taxane based chemotherapy. There is projected to be nearly 2.9 billion¹⁹ USD in sales of taxanes, indicating that utilization of these drugs will greatly increase over the next few years for both breast and other types of cancers. Therefore, the ocular adverse events studied will become more significant in the near future.

Our study has strengths and limitations. This was the first and largest study of women who used a taxane (with aged-matched controls using tamoxifen) that examined three important ocular adverse events. The strength of our study is use of a comparator group and adjustment for other confounder or risk factors. Although most taxanes in women are used for breast cancer, it is possible that they were used for other types of cancer. However, we don ‘t believe different types of cancers would alter the risk of these three ocular adverse events. As with all pharmacoepidemiologic studies that use claims data we did not have access to patients ‘ charts for outcome validation.

In a cohort of women who were using taxane chemotherapy agents, there was an elevated risk for epiphora, optic neuropathy and a less precise increase in risk for cystoid macular edema. Ophthalmologists and oncologists should be aware of these adverse events in women with breast cancer who use these drugs. Early identification of such events may help in treatment of complications and lead to better outcomes and quality of life. Future studies should confirm these results.